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Conclusion: In this large study of mostly myeloablative, T-
cell deplete, allogeneic transplant patients the presence of
donor vs recipient Minor ABO-I did not signiﬁcantly impact
critical long term outcomes.
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Background: VRE is a common cause of BSI and daptomycin
is often used as ﬁrst-line therapy. The Clinical and Laboratory
Standards Institute (CLSI) deﬁnes VRE isolates with dapto-
mycin MIC (D-MIC) of 4 mg/L as susceptible. Clinical sig-
niﬁcance and treatment outcomes of VRE BSI episodes with
D-MIC of 4, compared to those with D-MIC of 2 is currently
undeﬁned.
Patients and Methods: A single-center retrospective chart
review of adults with hematologic malignancies and HSCT
(autologous and allogeneic) recipients diagnosed with VRE
BSI between September 2006 and September 2014 was
performed. D-MICs were determined using Etest and VRE
isolates with MICs <2 or >4 were excluded from the study.
Only the ﬁrst VRE BSI episode per patient was included.
Results: 53 BSI episodes were identiﬁed in 59 patients (27
allogeneic and 3 autologous HSCT; 29 with hematologic
malignancies); of which 47.2% (25 of 53) and 52.8% (28 of 53)
were due to isolates with D-MICs of 4 and 2 respectively. The
median duration of bacteremia (4 versus 3 days; p ¼ 0.20),
median duration of neutropenia (15 vs. 17 days; p ¼ 0.78),
and Pitt Bacteremia Score (p ¼ 0.51) did not differ signiﬁ-
cantly between patients with VRE BSI due to D-MICs of 4 and
2. The all-cause 30-day mortality after onset of BSI was 44.4%
(D-MIC: 4) vs. 55.6% (D-MIC: 2) in HSCT recipients and 33.3%
(D-MIC: 4) vs. 55.6% (D-MIC: 2) in patients with hematologic
malignancies. 100% of the episodes were due to Enterococcusfaecium, with central venous catheters identiﬁed as the most
common source of BSI. Daptomycin monotherapy was the
most common treatment choice, used in 80% (47 of 59) of the
BSI episodes.
Conclusion: The all-cause 30-day mortality, duration and
severity of bacteremia did not appear to be different between
VRE BSI episodes with D-MICs of 4 versus 2 in HSCT re-
cipients and patients with hematologic malignancies.
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Introduction: The outcome of allo-SCT in patients with poor
risk leukemia is still hampered by GVHD and relapse. The
innate immune system has been reported to contribute to
tumor control, with lower incidence of GVHD. Speciﬁc
depletion of abT-cells e key players in the development of
GVHD e will render NK cells and gd T cells within the allo-
graft. Recently reported results have shown the great
promise of this approach in haploidentical transplantations.
Within this study, we aim to extend abT-cell depleted allo-
SCT to patients with a MRD or MUD.
Methods: Patients with either ‘poor-risk’ or ‘very poor-risk’
leukemia were included in this phase I study. Either HLA
matched siblings (MRD) or HLA matched (9 or 10/10) unre-
lated donors (MUD) were eligible. abT-cell reduction was
performed by negative selection with anti-abTCR antibodies
in combination with magnetic microbeads, using the auto-
mated CliniMACS device (Miltenyi Biotec, Bergisch Gladbach,
Germany). The maximal contamination with abT-cells for all
dose levels was 5x105/kg. The conditioning regimen con-
sisted of: ATG (Genzyme) 4 or 6 mg/m2 + ﬂudarabine 120
mg/m2 + busilvex AUC¼90 followed by abT-cell depleted
grafts from matched related or unrelated donors. No addi-
tional immune suppression was given after allo-SCT.
Results: Products for 15 patients have been successfully
processed and used for abT-cell depleted allo-SCT between
2013 and 2014. A w4 log depletion of abT-cells has been
observed in the product with a recovery of w75% of CD34+
cells. The combination of ATG/ﬂudarabine/busilvex was well
tolerated with a hematological recovery within 3 weeks.
Primary engraftment (chimerism > 95%) was observed in all
patients. Immune reconstitution primarily consisted of
innate cells (NK cells and gd T cells) the ﬁrst 6 months post
